Vimarsana
Biggest News Aggregation in the World

Page 3 - Sue Stuart News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sue Stuart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sue Stuart Today - Breaking & Trending Today

Investegate |Synairgen plc Announcements | Synairgen plc: Inclusion in US ACTIV-2 trial - Vimarsana News

Investegate |Synairgen plc Announcements | Synairgen plc: Inclusion in US ACTIV-2 trial

About Synairgen  Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a  broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen's differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorde...

Emergex Vaccines signs Collaboration Agreement with Brazil's Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine - Brazil Business Today - Vimarsana News

Emergex Vaccines signs Collaboration Agreement with Brazil's Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine - Brazil Business Today

PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world's most respected public health research institutions Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’)...

Emergex Vaccines signs Collaboration Agreement with Brazil's Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine - Vimarsana News

Emergex Vaccines signs Collaboration Agreement with Brazil's Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

News Category Global Banking & Finance Reviews Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one o...

Synairgen plc: COVID-19 Clinical Programme Update - Vimarsana News

Synairgen plc: COVID-19 Clinical Programme Update

Synairgen plc: COVID-19 Clinical Programme Update Phase III trial design adapted which will expedite results Phase III trial to commence dosing in UK imminently Southampton, UK - 18 December 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces updates to the Company's Phase III trial design evaluating SNG001 as a treatment for patients with COVID-19 and positive progress on the regulatory path. Update to Phase III trial (SG018) protocol in COVID-19 patients Following discussions with the regulatory agencies, the trial has been amended as f...

Investegate |Vectura Group plc Announcements | Vectura Group plc: $11m milestone on US FDA Generic Advair approval - Vimarsana News

Investegate |Vectura Group plc Announcements | Vectura Group plc: $11m milestone on US FDA Generic Advair approval

Vectura Group plc Elizabeth Knowles - VP Investor Relations                         +44 (0)7767 160 565   Mary-Jane Elliott / Sue Stuart / David Daley   About Vectura Vectura is a provider of innovative inhaled drug delivery solutions that enable partners and customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapie...